Feb 18, 2022

Featuring perspectives from Prof Karim Fizazi, including the following topics:

• Introduction (0:00)
• Journal Club with Prof Karim Fizazi, MD, PhD (3:40)
• Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Nataliya Mar, MD (16:39)
• Comments on the PEACE-1 trial by A Oliver Sartor, MD (21:58)
• Case: Two patients with prostate cancer who received a PARP inhibitor — Helen H Moon, MD (32:18)
• Case: A man in his mid-60s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Rohit Gosain, MD (37:59)
• Second Opinion by Simon Chowdhury, MD, PhD: A man in his late 60s with mCRPC and a germline BRCA2 mutation (Zanetta S Lamar, MD) (41:40)
• Comments on the TheraP trial by Dr Sartor (55:29)
• Immune Checkpoint Inhibitors in mCRPC (58:48)

CME information and select publications